Clinical Trial Search

Primary: Pain Score at the Time of Osmotic Dilator Insertion — 3.5; 4.0 score on a scale

Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293

Primary: Patient Preference — 14; 4; 2 Participants

Primary: Sensation as Indicated by the Volume of Water Filled (ml) at the Time of Patient Perception of First Sensation, First Urge to Void, Strong Urge to Void, and Full Bladder…

Primary: Change in Lip Vessel's Thickness — 0.833; 0.360 µm

Primary: Percentage of Participants With Any Injection Site Nodule and/or Papule — 30.52; 24.84 percentage of participants

Primary: Duration of Severe-range Hypertension After Delivery — 38.0; 35.3 hours — p=0.3

Primary: Number of Participants Who Develop Delayed Cerebral Vasospasm — 2 Participants

Primary: Blood Concentration of the Active Metabolite of Clopidogrel — 14.45; 13.80 ng/ml — p=0.66

Primary: Depression Severity — 22.5; 12.0; 14.1 score on a scale — p=0.04

Primary: Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo — 18; 27 Participants

Primary: Change in EGP From Baseline to Post-oral Glucose Load. — -0.03; -0.18; 0.14; -0.08 mg/kg.min

Primary: Morphine Milligram Equivalents (MME) of Oxycodone Tablets Taken by Patient — 1089.7; 777.1 Morphine Milligram Equivalents (MME)

Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…

Primary: Number of Participants With Confirmed Allergy Status — 28; 6; 6 Participants